Conformationally Restricted Beta-2 Agonists for Selective Receptor Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current β-adrenergic receptor agonists often cause undesirable side effects due to non-selective activation of β1 and β2 adrenergic receptors, leading to elevated blood pressure and other cardiovascular issues, which limits their effectiveness in treating bronchoconstrictive diseases and conditions like asthma and COPD.
Innovation Solution
Development of conformationally restricted analogs of catecholamine compounds that selectively activate β2 adrenergic receptors with high specificity, reducing the activation of β1 receptors and thereby minimizing side effects such as elevated blood pressure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective beta-adrenergic receptor agonists are used to treat bronchoconstrictive diseases, then bronchodilation effect is achieved, but cardiovascular side effects occur due to beta-1 receptor activation
Solution Approach 1:
The patent applies local quality by introducing conformational restrictions at specific positions of the catecholamine molecule (using cyclic structures like cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl rings) to create different spatial configurations that selectively fit the beta-2 receptor binding site while excluding beta-1 receptor activation. This modifies the local spatial arrangement of functional groups to achieve receptor subtype discrimination.
Solution Approach 2:
The patent changes the conformational parameters of the catecholamine molecule by incorporating rigid cyclic structures that lock the molecule into specific three-dimensional configurations. This alters the spatial orientation and distance between key functional groups (hydroxyl groups, amino group, and aromatic ring), enabling selective binding to beta-2 adrenergic receptors while preventing activation of beta-1 receptors.
2Object-affected harmful factors
If conformationally restricted analogs are designed to achieve beta-2 selectivity, then side effects are reduced, but molecular complexity increases
Solution Approach 1:
The patent segments the flexible catecholamine molecule by introducing distinct cyclic structural units (cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl rings) at the propyl chain position. This segmentation creates discrete conformational states with defined spatial arrangements, transforming a flexible chain into a structured framework that achieves selective receptor binding through controlled molecular geometry rather than random conformational sampling.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These β2 selective adrenergic receptor agonists effectively treat bronchoconstrictive diseases and conditions while reducing undesirable side effects associated with β1 receptor activation, providing a safer and more targeted therapeutic approach.
Implementation Method 1
Stimulation of the beta-adrenergic receptors (RAR), including subtypes beta1, beta2 and beta3AR, by adrenaline and noradrenaline leads to the activation of Gs proteins
Implementation Method 2
Stimulation of the beta-adrenergic receptors (RAR), including subtypes beta1, beta2 and beta3AR, by adrenaline and noradrenaline leads to the activation of Gs proteins, resulting in activation of adenylyl cyclase and subsequent accumulation of cAMP
Data Source
AI summary
Aspects of the present disclosure include conformationally restricted analogs of catecholamine type compounds (e.g., isoprenaline, adrenaline, noradrenaline) which activate β2AR with high selectivity over β1AR. The subject beta-2 selective adrenergic receptor agonist compounds may serve as bronchiodilators and find use in the treatment of a variety of bronchoconstrictive diseases and conditions. Also provided are compositions and methods for treating preterm labor. A method of treating acute asthma including administration of a subject compound to a subject in need thereof is provided. The subject method can provide for reduced undesirable side effects associated with non-selective β-adrenergic receptor agonism, such as inotropic and chronotropic effects that leads to elevated blood pressure. The compounds can also be used to prevent or treat heart failure. Kits and compositions for practicing the subject methods are also provided.